

SYMPOSIUM:

The Art of Patient Enrollment in Genitourinary Oncology Clinical Trials

THURSDAY, OCTOBER 17 • 7:30 – 930 AM CT • CRYSTAL A (LOBBY LEVEL)

Clinical trial summary (S1937)

Adding the New Drug Eribulin to Gemcitabine Chemotherapy for Urothelial Bladder Cancer That Has Spread

What is the purpose of this clinical trial?

This study tests combining 2 chemotherapy drugs, eribulin and gemcitabine, to treat bladder cancer that has spread to other places in the body.

- **Eribulin** is a chemotherapy drug that is used to treat other types of cancer.
- **Gemcitabine** is a chemotherapy drug that doctors currently use to treat bladder cancer.

The Food and Drug Administration (FDA) has approved several different chemotherapy drugs for bladder cancer that has spread. This study will compare the combination of eribulin and gemcitabine to the current treatment options.

This trial is set up to find out:

- If chemotherapy using both eribulin and gemcitabine can help people with bladder cancer live longer than the current treatments
- If chemotherapy using both eribulin and gemcitabine can help control bladder cancer for a longer time than the current treatments

Clinical trial summary (S2200)

Adding The Drug Atezolizumab to a Usual Treatment for Advanced Papillary Renal Cell Cancer

What is the purpose of this clinical trial?

Papillary renal cell cancer is a rare type of kidney cancer that forms in small tubes of the kidney. This study will test treatment for papillary renal cell cancer that has spread to other places in the body. Researchers want to find out if a usual treatment for this cancer can be improved by combining it with the study drug atezolizumab.

This trial is set up to find out:

- If adding the study drug to usual treatment helps people live longer with this type of kidney cancer before the cancer gets worse
- How people with this type of kidney cancer respond to usual treatment plus the study drug compared to usual treatment without the study drug
- What side effects people have with the different treatments

Why is this trial important?

Advanced kidney cancer can be difficult to treat, and doctors want to improve treatment for it. The study drug atezolizumab is an immunotherapy drug that may help the immune system fight cancer. It is approved by the Food and Drug Administration (FDA) to treat other advanced cancers, including some types of kidney cancer. Adding it to usual treatment may work better than the usual treatment alone for advanced papillary renal cell cancer.

WHY

This trial papillary other pl
Talk with who can

FALL MEETING | CHICAGO, IL | OCTOBER 16-19, 2024

THANKS TO

Our Top Accruers

Patient volunteers power our trials — and SWOG members connect us to them.

SWOG-Credited Registrations to SWOG Managed Trials January 1 through June 30, 2024. We appreciate their hard work and their confidence in our research.

TOP ACCRUING SITES

LAPS/MEMBER

- Moffitt Cancer Center
- University of Texas Health Science Center at San Antonio
- Instituto Nacional De Cancerologia de Mexico
- Northwestern University LAPS
- University of Arkansas for Medical Sciences

TOP ACCRUING SITES

NCORP

- Heartland Cancer Research NCORP
- Southeast Clinical Oncology Consortium NCORP
- Kaiser Permanente NCI Community Oncology Research Program
- Michigan Cancer Research Consortium NCORP
- Cancer Research of Wisconsin and Northern Michigan Consortium
- University of Kansas Cancer Center

This workshop on state-of-the-art accrual and retention strategies will explore best practices for robust trial accrual, with nuances specific to GU trials.

It features some of our top-accruing GU investigators and our patient advocates

- investigators from academic, NCORP, community, and VA sites
- specialists in biostatistics, radiation oncology, and medical oncology

Topics will include

- Building a balanced portfolio of GU trials at your site
- Best practices
 - Introducing a trial to a patient
 - Informed consent
 - Investigator and patient perspectives
 - Roles of clinical research coordinators and nurses
- Panel discussion on successful accrual to multidisciplinary and/or multimodal trials
- Exceeding expectations: setting the stage for robust, diverse accrual
 - Successful infrastructure models
 - Overcoming resource limitations
 - Improving enrollment diversity
 - Patient-centered, culturally sensitive recruitment

Early-career investigators are strongly encouraged to attend! But this session will have value for all SWOG members.